Loading…
ACET
Adicet Bio, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 007002207
$9.15+2.41%Price as of Sep 22, 22:38 UTC · updated once a day, after the close
Key metrics
- Market cap
- $85.61M
- P/E
- —
- Forward P/E
- —
- P/B
- 0.8x
- Dividend yield
- —
- Payout
- —
- EPS
- -$10.42
- ROE
- -78.08%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 1.59
- 52-week high
- $17.44
- 52-week low
- $6.01
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -93.4% over 5Y.
today you would have $71.91▼ -92.8%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 8 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $8.42 | $15.39 | $30.24 | $143.04 | $279.84 | $224.80 | $166.88 | $965.44 | |
| P/B | 1.1x | 0.5x | 0.4x | 0.9x | 1.3x | 2.3x | 4.1x | — | — |
| EPS | -$16.95 | -$21.33 | -$52.96 | -$27.20 |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| INCRIntercure Ltd. | $5.78 | — | 0.8x | — | -9.27% | $86.72M |
| LUNGPulmonx Corp | $2.00 | — | 2.2x | — | -88.87% | $84.47M |
| ECORelectroCore, Inc. | $9.63 | — | — | — | — | $86.78M |
| ALDXAldeyra Therapeutics, Inc. | $1.40 |
About the company
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
- 102
- Boston, United States
Company description provided by Yahoo Finance.